SPP2 and Sepsis: SPP2 was first evaluated for its individual ability to protect against lethal sepsis challenge with a ST-3 strain of S. pneumoniae (AR003) in a challenge model under conditions where immunization with PCV13 containing CPS3 is completely protective.